Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513.

被引:2
作者
Chiorean, E. Gabriela
McDonough, Shannon
Philip, Philip Agop
Swisher, Elizabeth M.
Pishvaian, Michael J.
Guthrie, Katherine
Lowy, Andrew M.
Hochster, Howard S.
机构
[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[2] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[6] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[7] Yale Canc Ctr, New Haven, CT USA
关键词
D O I
10.1200/JCO.2017.35.15_suppl.TPS4147
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
TPS4147
引用
收藏
页数:6
相关论文
empty
未找到相关数据